Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Celecoxib with Radiation for Head and Neck Cancer
NCT00970502Phase 2Completed
- Start
- Feb 2007
- Primary completion
- Nov 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of erlotinib and celecoxib in head and neck cancer (HNC). Primary endpoint: Toxicity at 30 days. Started Feb 2007; status: completed.
02
Drugs
erlotinibcelecoxib
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00970502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00970502.